Hepatic arterial infusion chemotherapy with anti-angiogenesis agents and immune checkpoint inhibitors for unresectable hepatocellular carcinoma and meta-analysis

Table 1 P value of different interventions

Intervention	OR	Intervention	HR
HAIC	0.9520107	HAIC + Sorafenib	0.03757857
HAIC + Sorafenib	0.9420071	HAIC	0.09333929
SIRT	0.8131607	TACE + Lenvatinib	0.098075
TACE + Lenvatinib	0.8014429	Sintilimab + Bevacizumabbiosimila	0.24973929
Sintilimab + Bevacizumabbiosimila	0.6559643	Camrelizumab + Rivoceranib	0.30909286
Lenvatinib + Pembrolizumab	0.5922857	Atezolizumab + Bevacizumab	0.35838929
Camrelizumab + Rivoceranib	0.5853643	Lenvatinib + Pembrolizumab	0.51200714
Durvalumab + Tremelimumab	0.523425	Durvalumab + Tremelimumab	0.52634286
Durvalumab	0.3891893	Donafenib	0.62278571
Atezolizumab + Bevacizumab	0.3369036	Tislelizumab	0.66164643
Lenvatinib	0.3254286	Nivolumab	0.67260357
Tislelizumab	0.2732107	Durvalumab	0.68975714
Nivolumab	0.1859964	Lenvatinib	0.78121071
Donafenib	0.1165357	Sorafenib	0.9135
Sorafenib	0.007075	SIRT	0.97393214

HAIC: Hepatic arterial infusion chemotherapy; TACE: Transcatheter arterial chemoembolization; SIRT: Selective internal radiation therapy; HR: Hazard ratio; OR: Odds ratio.